ANCA Vasculitis: Can Treatment Use Fewer Steroids?

What does PEXIVAS show about reducing steroid exposure?

The scrutiny surrounding avacopan makes the evidence for other approaches to reducing steroid exposure especially relevant. In April, the FDA proposed withdrawing Tavneos approval after questioning the reliability of its pivotal efficacy evidence and identifying additional safety concerns. That development raises a separate clinical question: what evidence supports reducing glucocorticoids within established treatment regimens? [FDA announcement](https://www.fda.gov/drugs/drug-alerts-and-statements/cder-proposes-withdraw-approval-tavneos).

Published in The New England Journal of Medicine in 2020, PEXIVAS enrolled 704 people with severe ANCA-associated vasculitis involving impaired kidney function or bleeding into the lungs. Participants received background immunosuppressive treatment while researchers compared reduced-dose and standard-dose oral glucocorticoid schedules. The reduced-dose schedule met the trial's noninferiority criterion for the combined outcome of death or end-stage kidney disease. Serious infections were less frequent during the first year. [PEXIVAS trial](https://www.nejm.org/doi/full/10.1056/NEJMoa1803537).

Noninferiority means the findings stayed within a prespecified boundary for an acceptable difference; it does not establish that treatments are identical. PEXIVAS supports a defined tapering strategy with accompanying treatment and monitoring. It did not test stopping steroids abruptly or treating severe vasculitis without other immunosuppressive medicines.

Can lower steroid doses work alongside rituximab?

The LoVAS randomized trial, published in JAMA in 2021, enrolled 140 patients in Japan. Both groups received rituximab, with either a reduced-dose or conventional high-dose glucocorticoid regimen. At six months, remission occurred in 49 of 69 analyzed patients receiving the reduced-dose regimen and 45 of 65 receiving the high-dose regimen. These results met the study's prespecified noninferiority criterion. Serious adverse events and serious infections affected fewer patients in the reduced-dose group. [LoVAS trial](https://jamanetwork.com/journals/jama/fullarticle/2780489).

The eligibility criteria limit how broadly the findings apply. Participants had newly diagnosed disease without severe glomerulonephritis or alveolar hemorrhage, meaning severe kidney inflammation or bleeding into the lungs. Most had myeloperoxidase-associated disease, which also affects interpretation of relapse risk. The authors acknowledged that the noninferiority margin might have been too wide. These findings support discussing a studied combination regimen; they do not establish that every patient can follow the same steroid reduction schedule.

How do clinicians choose a steroid-reduction strategy?

Reducing steroid exposure is one component of a broader treatment plan. The KDIGO 2024 guideline recommends glucocorticoids combined with rituximab or cyclophosphamide for initial treatment of new-onset ANCA-associated vasculitis. It also provides a tapering schedule informed by PEXIVAS. Decisions depend on factors including kidney impairment, previous treatment and whether disease is newly diagnosed or relapsing. Its avacopan recommendations predate the FDA's subsequent concerns and require consideration alongside current regulatory advice. [KDIGO guideline](https://kdigo.org/wp-content/uploads/2024/05/KDIGO-2024-ANCA-Vasculitis-Guideline-Update.pdf).

Controlling the initial episode and preventing future relapses are distinct treatment goals. Patients may need maintenance therapy after remission, even when their steroid dose becomes small. A useful specialist discussion therefore covers the planned taper, how disease activity will be monitored and which medicine will maintain remission. Neither PEXIVAS nor LoVAS directly establishes a replacement regimen for someone currently taking avacopan; that transition requires an individualized clinical assessment.